Jeff Galvin is the CEO and Founder of American Gene Technologies™ (AGT). He earned his BA degree in Economics from Harvard in 1981 and has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies, including one in the medical-technology arena that was sold to Varian, the leading maker of linear accelerators used in cancer therapy. Following his startup experience, he retired to become an Angel Investor in real estate and high tech. He came out of retirement to found and fund AGT after meeting Roscoe Brady at NIH.
Jeff Galvin, CEO and Founder at American Gene Technologies™ (AGT)
Newsletter
Get the Global Trial Accelerators™ newsletter
Practical insights on first-in-human and early feasibility trials across medtech, biotech/biopharma and radiopharma, in your inbox.
Free. Unsubscribe anytime. See the bioaccess® Privacy Policy (opens in a new tab) and the newsletter platform's Terms of Service (opens in a new tab).
Recent Episodes
- Varun Kalaiarasan, PhD Researcher at University of Cincinnati
- Ryan Beal, Chief Executive Officer at Dyve Biosciences
- Sandi Schaible, Founder & President at Bonded in Science
- Gennaro Maida, CEO and Founder at Denovo Innovations Group
- Benjamin Holmes, Chief Executive Officer at Nanochon
- Allison Komiyama, CEO and Founder at Bluestocking Health, LLC
- Daniel Zequeto, Founder & CEO at ODC Life Sciences
- Satabhisa Mukhopadhyay, Founder & Chief Scientist at 4D Path Inc
- Deborah Morley, Director CV Strategy and Delivery at RQM+
- See all →